Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) on Friday, plunged -3.75% from the previous trading day, before settling in for the closing price of $3.20. Within the past 52 weeks, AMLX’s price has moved between $1.58 and $19.95.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 2300.59% over the last five years. The company achieved an average annual earnings per share of -623.81%. With a float of $41.15 million, this company’s outstanding shares have now reached $67.71 million.
The firm has a total of 384 workers. Let’s measure their productivity.
Amylyx Pharmaceuticals Inc (AMLX) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Amylyx Pharmaceuticals Inc is 39.55%, while institutional ownership is 61.70%. The most recent insider transaction that took place on Sep 12 ’24, was worth 101,368. In this transaction Chief Financial Officer of this company bought 40,000 shares at a rate of $2.53, taking the stock ownership to the 233,464 shares. Before that another transaction happened on Sep 05 ’24, when Company’s Director bought 50,000 for $2.13, making the entire transaction worth $106,590. This insider now owns 55,000 shares in total.
Amylyx Pharmaceuticals Inc (AMLX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -623.81% per share during the next fiscal year.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Trading Performance Indicators
Amylyx Pharmaceuticals Inc (AMLX) is currently performing well based on its current performance indicators. A quick ratio of 4.66 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.45, a number that is poised to hit -0.70 in the next quarter and is forecasted to reach -1.75 in one year’s time.
Technical Analysis of Amylyx Pharmaceuticals Inc (AMLX)
Analysing the last 5-days average volume posted by the [Amylyx Pharmaceuticals Inc, AMLX], we can find that recorded value of 1.42 million was lower than the volume posted last year of 2.1 million. As of the previous 9 days, the stock’s Stochastic %D was 70.05%. Additionally, its Average True Range was 0.19.
During the past 100 days, Amylyx Pharmaceuticals Inc’s (AMLX) raw stochastic average was set at 85.51%, which indicates a significant increase from 73.58% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.05% in the past 14 days, which was higher than the 69.80% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.30, while its 200-day Moving Average is $6.24. Now, the first resistance to watch is $3.22. This is followed by the second major resistance level at $3.37. The third major resistance level sits at $3.45. If the price goes on to break the first support level at $2.99, it is likely to go to the next support level at $2.91. Should the price break the second support level, the third support level stands at $2.77.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Key Stats
Market capitalization of the company is 209.69 million based on 68,006K outstanding shares. Right now, sales total 380,790 K and income totals 49,270 K. The company made 88,640 K in profit during its latest quarter, and -118,790 K in sales during its previous quarter.
